STARPharmaceuticals
Strides Pharma Science Ltd — Cash Flow Statement
₹937.75
+1.19%
Strides Pharma Science Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 441.88 Cr | 582.91 Cr | -50.53 Cr | -401.20 Cr | — |
| Repayment Of Debt | -320.14 Cr | -422.27 Cr | -255.02 Cr | -268.13 Cr | — |
| Issuance Of Debt | 129.15 Cr | 107.32 Cr | 330.40 Cr | 450.66 Cr | — |
| Issuance Of Capital Stock | 6.10 Cr | 52.67 Cr | 38.47 Cr | 3.62 Cr | — |
| Capital Expenditure | -242.50 Cr | -118.15 Cr | -94.94 Cr | -143.38 Cr | — |
| End Cash Position | 112.56 Cr | 161.02 Cr | 303.50 Cr | 170.73 Cr | — |
| Other Cash Adjustment Outside Changein Cash | -0.02 Cr | -0.14 Cr | -0.34 Cr | — | — |
| Beginning Cash Position | 161.02 Cr | 303.50 Cr | 170.73 Cr | 125.83 Cr | — |
| Effect Of Exchange Rate Changes | -0.54 Cr | 0.16 Cr | 0.15 Cr | 0.13 Cr | — |
| Changes In Cash | -47.90 Cr | -142.51 Cr | 132.96 Cr | 44.77 Cr | — |
| Financing Cash Flow | -642.58 Cr | -693.32 Cr | -213.92 Cr | 421.32 Cr | — |
| Net Other Financing Charges | 42.23 Cr | -311.95 Cr | — | — | 0.17 Cr |
| Interest Paid Cff | -249.62 Cr | -310.55 Cr | -224.21 Cr | -153.79 Cr | — |
| Cash Dividends Paid | -22.99 Cr | -13.52 Cr | — | -22.43 Cr | -17.91 Cr |
| Net Common Stock Issuance | 6.10 Cr | 52.67 Cr | 38.47 Cr | 3.62 Cr | — |
| Common Stock Issuance | 6.10 Cr | 52.67 Cr | 38.47 Cr | 3.62 Cr | — |
| Net Issuance Payments Of Debt | -394.03 Cr | -72.51 Cr | 24.93 Cr | 638.96 Cr | — |
| Net Short Term Debt Issuance | -203.03 Cr | 242.45 Cr | -50.45 Cr | 456.43 Cr | — |
| Net Long Term Debt Issuance | -190.99 Cr | -314.95 Cr | 75.38 Cr | 182.53 Cr | — |
| Long Term Debt Payments | -320.14 Cr | -422.27 Cr | -255.02 Cr | -268.13 Cr | — |
| Long Term Debt Issuance | 129.15 Cr | 107.32 Cr | 330.40 Cr | 450.66 Cr | — |
| Investing Cash Flow | -89.69 Cr | -150.25 Cr | 302.47 Cr | -118.73 Cr | — |
| Net Other Investing Changes | 2.10 Cr | -6.20 Cr | 1.84 Cr | 5.13 Cr | — |
| Interest Received Cfi | 13.35 Cr | 15.27 Cr | 6.90 Cr | 6.74 Cr | — |
| Net Investment Purchase And Sale | 33.17 Cr | -76.60 Cr | -137.90 Cr | 156.92 Cr | — |
| Sale Of Investment | 41.53 Cr | 1.80 Cr | 19.15 Cr | 216.09 Cr | — |
| Purchase Of Investment | -8.35 Cr | -78.40 Cr | -157.04 Cr | -59.17 Cr | — |
| Net Business Purchase And Sale | -7.88 Cr | 0.79 Cr | 519.31 Cr | -219.51 Cr | — |
| Sale Of Business | 0.00 | 6.67 Cr | 519.31 Cr | 0.00 | — |
| Purchase Of Business | -7.88 Cr | -5.88 Cr | 0.00 | -219.51 Cr | — |
| Net PPE Purchase And Sale | 68.10 Cr | 88.81 Cr | 7.26 Cr | 75.37 Cr | — |
| Sale Of PPE | 68.10 Cr | 88.81 Cr | 7.26 Cr | 75.37 Cr | — |
| Capital Expenditure Reported | -242.50 Cr | -118.15 Cr | -94.94 Cr | -143.38 Cr | — |
| Operating Cash Flow | 684.37 Cr | 701.07 Cr | 44.41 Cr | -257.81 Cr | — |
| Taxes Refund Paid | 67.04 Cr | 24.25 Cr | 87.64 Cr | 2.33 Cr | — |
| Change In Working Capital | -163.72 Cr | -78.73 Cr | -457.80 Cr | -189.90 Cr | — |
| Change In Payable | 104.93 Cr | -148.53 Cr | -102.28 Cr | -159.29 Cr | — |
| Change In Inventory | -217.02 Cr | 30.70 Cr | -8.14 Cr | 28.19 Cr | — |
| Change In Receivables | -51.63 Cr | 39.09 Cr | -347.38 Cr | -58.80 Cr | — |
| Other Non Cash Items | 193.58 Cr | 279.96 Cr | 134.49 Cr | 115.33 Cr | — |
| Stock Based Compensation | 1.61 Cr | 1.59 Cr | 1.30 Cr | -0.71 Cr | — |
| Provisionand Write Offof Assets | 1.08 Cr | 17.57 Cr | -0.84 Cr | 0.00 | — |
| Depreciation And Amortization | 192.26 Cr | 220.68 Cr | 243.25 Cr | 233.01 Cr | — |
| Amortization Cash Flow | 76.14 Cr | 71.55 Cr | 71.32 Cr | 59.73 Cr | — |
| Depreciation | 116.12 Cr | 149.13 Cr | 171.93 Cr | 173.28 Cr | — |
| Gain Loss On Investment Securities | -3.29K Cr | -54.22 Cr | -18.57 Cr | — | -13.94 Cr |
| Net Foreign Currency Exchange Gain Loss | 13.64 Cr | 20.89 Cr | 38.69 Cr | -2.07 Cr | — |
| Gain Loss On Sale Of PPE | -4.09 Cr | -1.43 Cr | -4.11 Cr | -11.25 Cr | — |
| Net Income From Continuing Operations | 3.68K Cr | -62.72 Cr | -267.63 Cr | -652.51 Cr | — |
| Gain Loss On Sale Of Business | — | 0.00 | -65.61 Cr | -40.42 Cr | -32.30 Cr |
| Common Stock Dividend Paid | — | — | 0.00 | -22.43 Cr | -17.91 Cr |
| Net Investment Properties Purchase And Sale | — | — | 1.90 Cr | 6.25 Cr | 8.84 Cr |
| Sale Of Investment Properties | — | — | 1.90 Cr | 6.25 Cr | 8.84 Cr |
| Short Term Debt Payments | — | — | — | — | -182.43 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Strides Pharma Science Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.